Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.41 |
| ▸ | STK17B | O94768 | 2/20 | 0.40 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.40 |
| ▸ | PIM1 | P11309 | 2/20 | 0.40 |
| ▸ | MAP3K9 | P80192 | 2/20 | 0.40 |
| ▸ | MAP3K11 | Q16584 | 2/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.40 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.40 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.40 |
| ▸ | MAPK15 | Q8TD08 | 1/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.40 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3411035 | 0.82 | IMPDH2 (0.58) | CA12CA2CA9PSEN1PSEN2 | |
| SCHEMBL155308 | 0.78 | LRRK2 (0.41) | CA12CA2CA9PSEN1PSEN2 | |
| SCHEMBL29877761 | 0.78 | LRRK2 (0.41) | CA12CA2CA9PSEN1PSEN2 | |
| SCHEMBL153885 | 0.77 | CA12 (0.50) | CA12CA2CA9IMPDH2LMNA | |
| SCHEMBL6123291 | 0.76 | MAPT (0.47) | CA12CA2CA9PSEN1PSEN2 | |
| SCHEMBL16063166 | 0.76 | KMT2A (0.51) | CA12CA2CA9LMNAPOLB | |
| SCHEMBL430455 | 0.74 | ALDH1A1 (0.47) | CA2CA9PSEN1PSEN2APH1B | |
| SCHEMBL154457 | 0.73 | IMPDH2 (0.45) | CA12CA2CA9IMPDH2POLB | |
| Hydrochloric Acid SCHEMBL6122860 | 0.72 | IMPDH2 (0.44) | CA12CA2CA9IMPDH2POLB | |
| SCHEMBL155437 | 0.72 | PSEN1 (0.38) | CA12CA2CA9PSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8901309-B2 | Fused triazoles for the treatment or prophylaxis of mild cognitive impairment | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-02 | — | — | US | disclosed |
| US-20140350260-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2014-11-27 | — | — | US | disclosed |
| US-8822699-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-02 | — | — | US | disclosed |
| US-20130178497-A1 | FUSED TRIAZOLES FOR THE TREATMENT OR PROPHYLAXIS OF MILD COGNITIVE IMPAIRMENT | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-11 | — | — | US | disclosed |
| US-20120142672-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-06-07 | — | — | US | disclosed |
| EP-2455380-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2012-05-23 | — | — | EP | disclosed |
| US-20120059030-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178497-A1 | FUSED TRIAZOLES FOR THE TREATMENT OR PROPHYLAXIS OF MILD COGNITIVE IMPAIRMENT | BACE1, BACE2, APP | CA12 3052/4885CA2 1776/4885CA9 2674/4885 |
| US-20120059030-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BACE1, BACE2, APP | CA12 1607/4885CA2 552/4885CA9 1194/4885 |
| US-20140350260-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BACE1, BACE2, APP | CA12 1607/4885CA2 552/4885CA9 1194/4885 |
| US-20120142672-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BACE1, APP, BACE2 | CA12 989/4885CA2 182/4885CA9 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.